Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge Due to FDA Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Stock Plunge: Shares of Aquestive Therapeutics fell approximately 40% intraday on Friday after the FDA identified deficiencies in its New Drug Application, significantly eroding market confidence in the company's future prospects.
- FDA Deficiency Warning: The FDA indicated that unidentified deficiencies currently hinder discussions regarding the drug's labeling and post-marketing requirements, raising concerns about the application's approvability ahead of the January 31, 2026 PDUFA action date.
- Legal Consultation Opportunity: Faruq & Faruqi is investigating potential claims against Aquestive Therapeutics and encourages investors who suffered significant losses to contact them directly, highlighting their commitment to protecting investor rights.
- Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, demonstrating its strong capabilities and influence in the securities law sector.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 9.50 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.340
Low
8.00
Averages
9.50
High
12.00
Current: 3.340
Low
8.00
Averages
9.50
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
